MedMira Inc. Files Patent Application for Next Generation Rapid Test

HALIFAX, March 13 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions, announced today that it has filed a patent application with the United States Patent Office for its new rapid test platform. MedMira's research & development team has been working on a next generation, rapid test based on the company's patented flow-through diagnostic technology. This next generation rapid test is built on the key quality and performance attributes that have enabled MedMira's rapid HIV and HIV/Hepatitis combination tests to obtain regulatory approvals from the most stringent regulatory authorities in the world, including United States, Canada, China, India, Russia, and Europe.